XML 65 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1

Equity (Tables)

12 Months Ended

Dec. 31, 2024

Summary of Stock Option Activity

A summary of the status of the options granted by Teva as of December 31, 2024, 2023 and 2022, and changes during the years ended on those dates, is presented below (the number of options represents ordinary shares exercisable in respect thereof).

		Year ended December 31,
		2024								2023								2022
		Number (in thousands)				Weighted average exercise price				Number (in thousands)				Weighted average exercise price				Number (in thousands)				Weighted average exercise price
Balance outstanding at beginning of year			22,703			$	36.89				24,119			$	36.83				29,015			$	36.96
Changes during the year:
Exercised			(1,284	)			15.37				—				—				—				—
Forfeited			(1,211	)			34.13				(885	)			34.65				(2,378	)			33.77
Expired			(2,495	)			48.84				(531	)			37.57				(2,518	)			41.26
Balance outstanding at end of year			17,713				39.96				22,703				36.89				24,119				36.83
Balance exercisable at end of year			17,713				39.96				22,703				36.89				24,119				36.83

Schedule of Ordinary Shares Issued Upon Vested Options

The following table summarizes information as of December 31, 2024, regarding the number of ordinary shares issuable upon vested options:

Number of ordinary shares issuable upon exercise of vested options
Range of exercise prices		Balance at end of period (in thousands)				Weighted average exercise price				Weighted average remaining life
		Number of shares				$				Years
$15.01 - $25.00			6,152				18.96				3.14
$25.01 - $35.00			5,167				34.67				2.16
$35.01 - $45.00			57				37.70				1.92
$45.01 - $55.00			2,987				53.25				1.28
$55.01 - $65.00			3,350				59.01				0.34
Total			17,713				36.96				2.01

Schedule of the Number of RSUs Issued and Outstanding

The following table summarizes information about the number of RSUs and PSUs granted and outstanding:

		Year ended December 31,
		2024								2023								2022
		Number (in thousands)				Weighted average grant date fair value				Number (in thousands)				Weighted average grant date fair value				Number (in thousands)				Weighted average grant date fair value
Balance outstanding at beginning of year			35,664			$	9.07				32,302			$	9.11				24,412			$	11.58
Granted			11,557				13.66				16,608				9.77				18,755				7.42
Vested			(11,464	)			9.46				(10,195	)			10.28				(7,571	)			13.02
Forfeited			(1,947	)			9.81				(3,052	)			9.81				(3,293	)			9.81
Balance outstanding at end of year			33,810				10.46				35,664				9.07				32,302				9.11

Summary of Company Expenses Compensation Costs Based on Grant Date Fair Value

The Company expenses compensation costs based on the grant-date fair value. For the years ended December 31, 2024, 2023 and 2022, the Company recorded stock-based compensation costs as follows:

		Year ended December 31,
		2024				2023				2022
		(U.S. $ in millions)
Employee stock options		$	—			$	—			$	2
RSUs and PSUs			123				121				122
Total stock-based compensation expense			123				121				124
Tax effect on stock-based compensation expense			11				11				9
Net effect		$	112			$	110			$	115

Accumulated Other Comprehensive Income/(Loss) (Net of Tax)

The components of accumulated other comprehensive loss attributable to Teva are presented in the table below:

		Net Unrealized Gains (Losses)								Benefit Plans
		Foreign currency translation adjustments				Derivative financial instruments				Actuarial gains(losses) and prior service (costs) credits				Total
		(U.S. $ in millions)
Balance as of January 1, 2022		$	(2,274	)			(324	)			(85	)			(2,683	)
Other comprehensive income(loss) before reclassifications			(223	)			—				40				(183	)
Amounts reclassified to the statements of income			—				29				27				56
Net other comprehensive income(loss) before tax			(223	)			29				67				(127	)
Corresponding income tax			(17	)			—				(10	)			(27	)
Net other comprehensive income(loss) after tax*			(240	)			29				57				(154	)
Balance as of December 31, 2022			(2,514	)			(295	)			(28	)			(2,838	)
Other comprehensive income(loss) before reclassifications			167				(1	)			(17	)			149
Amounts reclassified to the statements of income			—				30				(4	)			26
Net other comprehensive income(loss) before tax			167				29				(21	)			175
Corresponding income tax			(37	)			—				3				(34	)
Net other comprehensive income(loss) after tax*			130				29				(18	)			141
Balance as of December 31, 2023			(2,384	)			(266	)			(46	)			(2,697	)
Other comprehensive income(loss) before reclassifications			(456	)							(1	)			(457	)
Amounts reclassified to the statements of income			—				28				(6	)			22
Net other comprehensive income(loss) before tax			(456	)			28				(7	)			(434	)
Corresponding income tax			(17	)			—				1				(16	)
Net other comprehensive income(loss) after tax*			(473	)			28				(6	)			(450	)
Balance as of December 31, 2024		$	(2,857	)		$	(238	)		$	(52	)		$	(3,148	)

* Amounts do not include foreign currency translation adjustments attributable to non-controlling interests of $61 million loss in 2024, $50 million loss in 2023 and $116 million loss in 2022.

X

- Definition

Tabular disclosure of share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of accumulated other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20

+ Details

Name:	us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (e)(2)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration